Depression and anxiety modify cognitive concerns associated with amyloid and early clinical impairment.
Neuropsychology · 2026
DOI: 10.1037/neu0001086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychology, 2026. Verfasst von Shana D Stites und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania. Hauptthemen laut MEDLINE: Anxiety, Depression, Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Alzheimer's Association, National Institutes of Health; National Institute on Aging.
Themen: Depression
Abstract (Originalsprache)
OBJECTIVE: Cognitive concerns (CCs) are common for patients with Alzheimer's disease (AD) dementia. We explore anxiety, depression, and clinical impairment as moderators of CCs in early AD. Understanding these associations may help inform efforts to advance early identification of disease progression in AD. METHOD: Data sources, selected based on requirements for availability of biomarker data and clinical assessment data, generated a pooled sample of adults ages 65+ with known amyloid status and cognitive function ranging from unimpaired (Clinical Dementia Rating global score [CDR-GS] = 0, n = 5,498) to early impairment (CDR-GS = 0.5, n = 504). Measures of CCs, anxiety, and depression were standardized to cognitively unimpaired groups. To model the difference in effects for different levels of anxiety and depression, we used mixed-effects quantile regression for median adjusted for age, sex, race, and educational years. All reported findings are p < .05. RESULTS: Higher CCs were associated with early clinical impairment (estimated change in median [β] = 15.5). CCs were higher with higher versus lower anxiety, except in unimpaired persons with elevated amyloid. In this latter group of unimpaired persons with elevated amyloid, CCs were higher with higher versus lower depression. CONCLUSION: In combination elevated amyloid, anxiety, and depression may offer data to guide clinical interpretation of CCs in early clinical impairment. The findings advance understanding of mood effects in early AD and inform specific measurement considerations. Future longitudinal studies are needed. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania.
- Division of Biostatistics, Department of Population Health, New York University Grossman School of Medicine.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania.
ORCID-Profile: Shana D Stites, Yidan Shi, Dawn Mechanic-Hamilton, David A Wolk
Förderung
- NIA NIH HHS
- Alzheimer's Association
- National Institutes of Health; National Institute on Aging
- National Institutes of Health
Zitieren
APA
Stites, S. D., Schumann, R., Shi, Y., Mechanic-Hamilton, D., Wolk, D. A., & Alzheimer’s Disease Neuroimaging Initiative (2026). Depression and anxiety modify cognitive concerns associated with amyloid and early clinical impairment. Neuropsychology. https://doi.org/10.1037/neu0001086
Vancouver
Stites SD, Schumann R, Shi Y, Mechanic-Hamilton D, Wolk DA, Alzheimer’s Disease Neuroimaging Initiative. Depression and anxiety modify cognitive concerns associated with amyloid and early clinical impairment. Neuropsychology. 2026. doi:10.1037/neu0001086
BibTeX
@article{Stites2026,
author = {Stites, Shana D and Schumann, Rosalie and Shi, Yidan and Mechanic-Hamilton, Dawn and Wolk, David A and Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Neuroimaging Initiative},
title = {Depression and anxiety modify cognitive concerns associated with amyloid and early clinical impairment},
journal = {Neuropsychology},
year = {2026},
doi = {10.1037/neu0001086}
}
EUVIMED